Stock Learning

Primeiro tratamento de catarata e refração com femtossegundo e novo tratamento excimer de presbiopia

First Cataract & Refractive Femtosecond Laser and New Excimer Treatment for Presbyopia

Primer láser femtosecond para cirugía de catarata y refractiva y nuevo tratamiento láser excimer para presbiopía

ROCHESTER, NY--(Marketwire - September 3, 2010) -  Bausch + Lomb, the global eye health company, has announced that it has concluded its acquisition of a portion of the assets and intellectual property for Miochol®-E from Affiliates of Novartis AG. Bausch + Lomb intends to complete the acquisition of the remaining assets and intellectual property upon the necessary regulatory clearance.

SUGAR LAND, TX--(Marketwire - September 3, 2010) -  Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The million dollar question continues to be "... is the economy better, is it getting worse, or is it somewhere in between?" Theories abound, talking heads offer wildly varied opinions, while in regard to active capital investment, the facts can only be found in hard data. If holding steady is considered a positive thing, a recent survey of Industrial Info's Pharmaceutical Tracker -- Online Database has revealed solid good news in terms of project activity for the month of September. The sector is holding its own with slightly more than $2 billion in 47 expected project starts this month, almost dead even with the 2009 figure of $2.4 billion.

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - September 3, 2010) -  Agennix AG (FRANKFURT: AGX) (XETRA: AGX) announced that data from a Phase II trial with talactoferrin in severe sepsis were presented today at the Sepsis 2010 International Symposium, which was hosted by the International Sepsis Forum, in Paris, France. The double-blind, placebo-controlled trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S. As previously reported, the Phase II trial achieved its primary endpoint of a reduction in 28-day all-cause mortality from 26.9% in the placebo arm to 14.4% in the talactoferrin arm (two-tailed p-value adjusted for cardiovascular dysfunction = 0.05, odds ratio by logistic regression analysis = 0.48), a 46% relative reduc

Medline Will Donate $1.00 for Every Case Sold to the National Breast Cancer Foundation

Virtual Pharma Rep(TM) E-Detailing Platform Brings a New Virtual Sales Approach to the Animal Health Industry

NEW YORK, NY--(Marketwire - September 2, 2010) -  MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, today announced a partnership with Thrasys, Inc. a provider of next-generation health information technology and solutions. MedLink and Thrasys have collaborated to provide interoperability and health record management based on SyntraNet from Thrasys, a cloud based Health Information Exchange (HIE) and Collaboration Network. SyntraNet enables more efficient and coordinated care across healthcare communities.

SILVER SPRING, MD--(Marketwire - September 2, 2010) -  A new laboratory, designed and built in accordance with international guidelines, opened September 1 in Maseru, Lesotho. The Makoanyane Military Hospital Laboratory now offers an expanded testing menu, including CD4 and Acid Fast Bacilli microscopy, and separate rooms dedicated to specimen reception, microbiology, chemistry, hematology and CD4 testing. The formerly limited, one-room hospital lab was transformed through a collaborative effort of The US Department of Defense and CDC's Global AIDS Program to support the Lesotho Defense Force's facility.

PUNE, INDIA--(Marketwire - September 2, 2010) -  Bilcare AG, part of the Bilcare group, today successfully completed all formalities related to the acquisition of the global films business from the INEOS Group. Bilcare AG had announced its intentions to acquire the business for a sum of Rs. 607 crores on August 2, 2010.

New Evidence Strongly Supports Prana's Therapeutic Strategy to Regulate Brain Metals

PHILADELPHIA, PA--(Marketwire - September 2, 2010) -  Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:

LONDON--(Marketwire - September 2, 2010) -

SDA Soybean Oil Is a Plant-Based Omega-3 That Efficiently Converts to Heart-Healthy EPA in the Body

Company Provides Corporate Update on Recent Sale of SunOpta BioProcess Inc. to Mascoma Corporation

NEW YORK, NY--(Marketwire - September 2, 2010) -  Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that the Board of Directors has voted to declare a dividend of $0.25 per share. The dividend will be paid to shareholders of record as of Wednesday, September 15, 2010. The dividend will be paid on Thursday, September 30, 2010. 

DALLAS, TX--(Marketwire - September 2, 2010) -  Metiscan, Inc. (PINKSHEETS: MTIZ) announced today shareholder points of interest discussed during the Company's nationwide teleconference yesterday. Mr. Bryan A. Scott, President & CEO, and Mr. Brian Hart, COO of Metiscan, provided deeper insight into its subsidiaries' markets, products, and near term objectives, as well as Metiscan's pursuit in listing on the OTCBB.

TUSTIN, CA--(Marketwire - September 2, 2010) -  Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter fiscal year 2011 on September 9, 2010 after market and will host a conference call and webcast at 4:30 p.m. EDT (1:30 p.m. PDT). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2010 of fiscal year 2011 and will review its clinical development programs.

LEIDEN, NETHERLANDS--(Marketwire - September 2, 2010) - Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has converted all of the remaining January 2010 bonds. The current number of outstanding shares as per today is 355,781,497 from 347,979,345 at August 24, 2010.

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - September 2, 2010) -

GENEVA, SWITZERLAND--(Marketwire - September 2, 2010) -

LifeCell to Distribute SPY in Plastics, GI and Head and Neck Surgery

COPENHAGEN, DENMARK--(Marketwire - September 1, 2010) -  Ib Sønderby, CEO of Zoar Invest and a stockholder of Elan Corporation, plc (NYSE: ELN), today announced that a conference call will be hosted on September 8, 2010 at 10:00 a.m. Eastern Daylight Time to introduce four potential Directors for the Elan Board and to discuss the current state of the Company. The call will be accompanied by a slide-show presentation, which will be available for download 15 minutes prior to the start of the call at www.SaveElan.com. A brief Q&A session will follow the prepared remarks.

SOUTH SAN FRANCISCO, CA--(Marketwire - September 1, 2010) -  Theravance, Inc. (NASDAQ: THRX) announced today that its Chief Executive Officer, Rick E Winningham, is scheduled to present at the following investor conferences in September 2010:

CARDIFF, CA--(Marketwire - September 1, 2010) -  NI Research has released the September issue of NeuroInvestment, which features a comprehensive review of Alzheimer's therapeutics, and a critical assessment of the pharma industry's premature rush to closure:

September 2010 Ophthalmology Journal Reports Rotterdam Study Update

XI'AN, CHINA--(Marketwire - September 1, 2010) -  Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 13, 2010 at 2:25pm Eastern time.

MARTINSRIED, GERMANY and MüNCHEN, GERMANY--(Marketwire - September 1, 2010) - MorphoSys AG / MorphoSys to Present at Three Investor Conferences in September processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Attention Business/Financial/Health Editors

Attention directeurs des rubriques affaires/finance/santé

JERUSALEM--(Marketwire - September 1, 2010) -  IDenta Corp. (PINKSHEETS: IDTA) CEO Yaacov Shoham announced today that the company has recently started negotiations with another chain store to sell the General Screening drug detector at their chain store locations. This new chain store is not one of the eight stores originally announced (published at May 28, 2009) but these negotiations are a direct result of the 70,000 kit order received from the other larger chain store.

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 1, 2010) -  www.stockcall.com/ offers investors comprehensive research on the major drug manufacturers industry and has completed analytical research on GlaxoSmithKline (NYSE: GSK) and Abbott Laboratories (NYSE: ABT). Register with us today at www.stockcall.com/ to have free access to these researches. 

Persistent Odor and VOC Reduction Capability Gets Favorable Response

Says Regenerative Medicine Is the Future of Stem Cell Science and AmStem Is Leading the Way

DNA Test Enables Physicians to Predict Medication Response in Patients for Effective Treatment

BEDFORD, MA--(Marketwire - September 1, 2010) -  Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in several upcoming investor conferences. These conferences include:

CAMBRIDGE, MA--(Marketwire - September 1, 2010) -  Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced that the Company has received an eighth extension of its waiver agreement with its Bond holders, allowing debt restructuring discussions to progress.

KNOXVILLE, TN--(Marketwire - September 1, 2010) -  Protein Discovery today announced that they have extended their protein extraction kit product line by launching the YPX Yeast Protein Extraction Kit. Unlike other yeast protein extraction products, the YPX kit does not use mechanical disruption to break open the tough cell walls of yeast. Using the YPX kit is much faster than carrying out conventional yeast lysis procedures used for protein extraction, and total protein yield is higher. The YPX kit protocol is simple and economical, and therefore offers substantial usability and cost benefits to researchers who wish to carry out experiments on many yeast cultures simultaneously. Finally, the YPX Yeast Protein Extraction Kit extracts the entire yeast proteome with nearly complete efficiency, and is uniquely compatible with quantitative yeast proteomics workflows which would otherwise be complicated by day-to-day and lab-to-lab variations in protein extraction efficiencies.

REDWOOD CITY, CA--(Marketwire - September 1, 2010) -  Yasheng Group (OTCQB: YHGG), is pleased to announce that its shares of common stock are now being quoted on the OTCQB as a U.S. registrant, a market tier for OTC stocks reserved for companies which are fully reporting to the Securities and Exchange Commission.

Yeast neutralizes malarial parasites in mice without side effects

MALVERN, PA--(Marketwire - September 1, 2010) -  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the following investor conferences:

BOSTON, MA--(Marketwire - September 1, 2010) - Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces that as a direct result of its recent very positive lab findings, it has moved forward to widen the Patent Filing for Global Patent Protection.

HILDEN, GERMANY and GERMANTOWN, MD--(Marketwire - September 1, 2010) -

SAN DIEGO, CA--(Marketwire - September 1, 2010) -  Recombinant human beta-interferon reduces the frequency of multiple sclerosis (MS) exacerbations and improves MS outcome measures. Unfortunately, current beta-interferon drug products form aggregates that provoke a neutralizing antibody response in MS patients, significantly reducing the effectiveness of the drug.

APUA President Says Mass Use of Antibiotics Is Cause for Concern

SAN CLEMENTE, CA--(Marketwire - August 31, 2010) -  Micro Identification Technologies, Inc. (OTCBB: MMTC) is a California-based public company that has developed, patented and produces a rapid microbial identification (ID) System that revolutionizes the bacteria ID process and can annually save thousands of lives and tens of millions of healthcare dollars. The MIT 1000 System identifies bacteria in minutes, not days, and at significant cost per test savings when compared to any conventional method -- it is not reliant on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis -- requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 10.2

NEW YORK, NY--(Marketwire - August 31, 2010) -  Somewhat hidden in the healthcare reform legislation that passed this spring was a tax credit and exclusivity extension for biologic drug developers, which, according to healthcare market research publisher Kalorama Information, may have a long-term impact on the market for cancer treatments. Kalorama predicts $25 billion to be earned from newly developed cancer treatments in the next five years, many of which will be biologics, according to its report "World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)."

Fly for MS Is the Largest Scale MS Event Ever Organized and the Longest Humanitarian Flight Ever Undertaken

NANTES, FRANCE--(Marketwire - August 31, 2010) - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, today announced its consolidated accounts (IFRS) for the first half of 2010 ended June 30, as well as its strategic perspectives.

ROCKVILLE, MD--(Marketwire - August 31, 2010) -  MarketResearch.com has announced the addition of TriMark Publications's new report "Point of Care Diagnostic Testing World Markets," to their collection of In Vitro Diagnostics market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2718862

ROCKVILLE, MD--(Marketwire - August 31, 2010) -  MarketResearch.com has announced the addition of BCC Research's new report "The Dynamic Media, Sera and Reagent Market in Biotechnology" to their collection of Biotechnology market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2748169

STOCKHOLM, SWEDEN--(Marketwire - August 31, 2010) -

BERKELEY, CA--(Marketwire - August 31, 2010) -  Dynavax Technologies Corporation (NASDAQ: DVAX) announced today a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to take a systems biology approach to study the differences between individuals that do or do not respond to vaccination against the Hepatitis B virus. This study will be one of several projects covered in a five-year, $17.6 million grant to Dr. Jacques Banchereau of the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program. 

Contains Updated Information on the Company's Five Operating Divisions

Saint Luke's Mid America Heart and Vascular Institute in Kansas City Successfully Implants Innovative Heart Failure Therapy through a Small Incision

TUSTIN, CA--(Marketwire - August 31, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.

MONROVIA, CA--(Marketwire - August 31, 2010) -  Niusule Biotech Corp. (OTCBB: NIUS) (the Company), a fast-growing, China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, today announced that it has signed a distribution agreement with China Nepstar Chain Drugstore Ltd, China's largest retail drugstore chain based on the number of directly operated stores.

SUWON, SOUTH KOREA--(Marketwire - August 30, 2010) - Neurotech Pharmaceuticals Co., Ltd. has begun dosing in the Phase 1 clinical testing of AAD-2004. AAD-2004 was developed as a dual function drug to remove free radicals and PGE₂, the key mediators of nerve injury in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The Phase 1 clinical trial was initiated to evaluate the safety, tolerability, and pharmacokinetics of AAD-2004 in healthy volunteers in April, 2010. The first two cohorts of the clinical study have been successfully completed without serious adverse events.

CHICAGO, IL--(Marketwire - August 30, 2010) - ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management's Discussion and Analysis today for the quarter ended June 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.

WAYNE, PA--(Marketwire - August 30, 2010) -  The Clinical and Laboratory Standards Institute (CLSI) and Association of Public Health Laboratories (APHL) are offering a teleconference to the health care community to learn more about the different considerations surrounding acceptance criteria on point-of-care (POC) glucose devices. The teleconference on September 30 is titled "POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor."

SHEFFIELD, MA--(Marketwire - August 30, 2010) -  The Autism Treatment Center of AmericaT is pleased to announce another amazing before-and-after video documenting Oscar's journey out of Autism using The Son-Rise Program. The video is available at http://www.youtube.com/watch?v=kXpf4hwO860, and includes Oscar's autistic behaviors, his achievements in The Son-Rise Program playroom, and his turnaround behavior as a socially active and verbal child. Oscar's parents credit his transformation to The Son-Rise Program, which they implemented after taking The Son-Rise Program Start-Up at The Autism Treatment Center of America in Sheffield, Massachusetts.

International Solutions Selects 1Click Ancillary(TM) as the Backbone of Its Ancillary Medical Services Needs

NEW YORK, NY--(Marketwire - August 30, 2010) -  Taglich Brothers, Inc. announces it initiated coverage of BioCurex, Inc.

ROCKVILLE, MD--(Marketwire - August 30, 2010) -  MarketResearch.com has announced the addition of Business Insights's new report "The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine" to their collection of Molecular Diagnostics market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2729698

Network of Leading Biobanks Gives Researchers Unprecedented Access to Highest Quality Biosamples From Most Major Diseases

OSLO, NORWAY--(Marketwire - August 30, 2010) -  Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1 September 2010. 

OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -  

"Know the Patient" Strategies Lay the Groundwork for Clinical Recruitment and Retention Success, Says Cutting Edge Information

ROCKVILLE, MD--(Marketwire - August 30, 2010) -  MarketResearch.com has announced the addition of GlobalData's new report "Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016" to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2750464

BUENA PARK, CA--(Marketwire - August 30, 2010) - SOHM, Inc. (PINKSHEETS: SHMN) announced today its generic pharmaceutical marketing program received a significant boost with up to 60 field staff and sales associates covering India's most populated states. The Company started its marketing initiative in the largest state of India, Uttar Pradesh, last year and it has been a huge success producing repeat orders, increasing the Company's market share in India and generating record revenue. SOHM's private label generic drugs are economically priced and being well received by consumers and the medical community in India.

JOHANNESBURG, SOUTH AFRICA--(Marketwire - August 30, 2010) -  www.RothmanResearch.com provides members a complete scrutiny of the drugs -- generic industry with thorough research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Sign up now on www.rothmanresearch.com to access these free reports.

Patent Allowance Protects Marina Biotech Key Delivery Technology for RNAi Therapeutics

BRISTOL, TN--(Marketwire - August 30, 2010) -  King Pharmaceuticals, Inc. (NYSE: KG) announced today the appointment of Jeffrey A. Bailey to the position of Chief Commercial Officer. Mr. Bailey will be responsible for the Company's commercial activities in the branded pharmaceutical business and will lead all Sales, Marketing, Managed Care, Sales Operations and Business Analytics. Importantly, he will lead King's strategic mission to be the leader in the effective and responsible treatment of pain. Mr. Bailey brings a wealth of experience in the pharmaceutical industry, most recently serving in a general management capacity for a significant profit center at Novartis and serving on the Novartis North American Executive Committee. Mr. Bailey has also held senior leadership roles for a private equity firm and for Johnson & Johnson where he was responsible for managing products in the pain therapeutic category and for

MONROVIA, CA--(Marketwire - August 30, 2010) -  Niusule Biotech Corp. (OTCBB: NIUS) (the Company), a fast growing China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, today announced they will present at the Rodman & Renshaw 2010 Annual Global Investment Conference. The conference will be held September 12-15, 2010, at The New York Palace Hotel.

BAGSVæRD, DENMARK--(Marketwire - August 30, 2010) -

PORT ST. LUCIE, FL--(Marketwire - August 30, 2010) -  RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, announces the opening of 10 new SmileShoppes in August, adding $5,000 a month in reoccurring revenue.

SIMSBURY, CT--(Marketwire - August 30, 2010) - As part of its business growth and diversification strategy, Ensign-Bickford Industries, Inc. "EBI" announced today that its subsidiary, EB Analytics, Inc. has acquired EnviroLogix Inc. ("ELIX"). ELIX is a Portland, Maine-based developer and manufacturer of rapid QuickStixT and QuickScanT agricultural test kits and readers. The terms of the transaction were not released.

BOSTON, MA--(Marketwire - August 30, 2010) -  Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces the appointment of Dr. Le Tien Canh, PhD to its Scientific Advisory Board.

BIOLASE to Host Call TODAY, August 30th at 11:00 a.m. E.D.T.

Expects Commercial Partner Novartis to Initiate Phase 3 Trial by Q1 2011

STOCKHOLM, SWEDEN--(Marketwire - August 29, 2010) - Portola Pharmaceuticals, Inc. today announced additional pharmacodynamic data from a pre-specified analysis of EXPLORE-Xa, a Phase 2 dose-finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. During a poster session at the European Society of Cardiology (ESC) Congress in Stockholm, Dr. Stuart Connolly, EXPLORE-Xa principal investigator and director, Division of Cardiology, McMaster University, Hamilton, Ontario, presented data from the analysis of three separate pharmacodynamic markers for anticoagulation (anti-Factor Xa units, thrombin generation and D-dimer) in plasma samples collected from patients enrolled in the EXPLORE-Xa clinical trial. The results showed a concentration dependent relationship and provided further evidence for the anticoagulant activity of betrixaban across all three doses studied in the clinical trial.